Background Dermatomyositis is a clinically distinct myopathy characterized by rash and a
complement-mediated microangiopathy that results in the destruction of muscle fibers. In …

Abstract purpose: The mainstay of pharmacologic therapy in patients with dermatomyositis is
corticosteroids. However, because patients sometimes become refractory to these drugs and …

Objective Polymyositis (PM) and dermatomyositis (DM) are inflammatory muscle diseases of
presumed autoimmune origin. Many possible interventions are available to treat these …

Background Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not
been extensively evaluated. Methods We conducted a randomized, placebo-controlled trial …

Abstract purpose: Polymyositis and dermatomyositis are inflammatory muscular diseases of
unknown cause. Many interventions are available to treat patients with these conditions …

Objective Polymyositis is a rare inflammatory muscular disease of unknown cause.
Corticosteroids and immunosuppressive drugs are the first choice of therapy but are not …

Dermatomyositis is a rare inflammatory myopathy with characteristic skin manifestations and
muscular weakness. The disease can be categorized as adult idiopathic, juvenile, or …

Dermatomyositis is one of the idiopathic inflammatory myopathies. It is characterized
clinically by progressive symmetrical proximal muscle weakness and a characteristic rash …

Since idiopathic inflammatory myositis is relatively uncommon, randomized placebo
controlled trials are rare. Although corticosteroids have not been tested in randomized …

There are three major subsets of the inflammatory myopathies: polymyositis (PM),
dermatomyositis (DM), and inclusion-body myositis (IBM). High-dose intravenous …